RADX novel imaging small molecule
Summary
An article belongs to this narrative if it is about Radiopharm Theranostics' novel imaging small molecule RAD101.
Hypotheses
Radiopharm Theranostics will announce RAD101 adoption at minimum 5 major hospital networks or imaging centers within 12 months post-Siemens deal, indicating successful commercial penetration and clinical validation.
RPTX stock price will appreciate by minimum 20% within 90 days of Siemens supply deal announcement as market recognizes expanded commercial distribution and revenue visibility for RAD101 imaging product.
The Siemens Healthineers supply agreement for RAD101 will drive Radiopharm Theranostics' revenue growth by at least 15% YoY within 12 months following deal announcement, as evidenced by increased imaging procedure volume and market adoption.